Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Aug. 31, 2020 | Oct. 15, 2020 | |
Document Information Line Items | ||
Entity Registrant Name | BIOMERICA INC | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --05-31 | |
Entity Common Stock, Shares Outstanding | 11,752,589 | |
Amendment Flag | false | |
Entity Central Index Key | 0000073290 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Aug. 31, 2020 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Interactive Data Current | Yes |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) | 3 Months Ended | |
Aug. 31, 2020 | Aug. 31, 2019 | |
Income Statement [Abstract] | ||
Net sales | $ 1,143,806 | $ 1,194,415 |
Cost of sales | (960,930) | (827,111) |
Gross Profit | 182,876 | 367,304 |
Operating Expenses: | ||
Selling, general and administrative | 1,164,564 | 506,397 |
Research and development | 674,693 | 370,466 |
Total operating expense | 1,839,257 | 876,863 |
Loss from operations | (1,656,381) | (509,559) |
Other Income: | ||
Dividend and interest income | 8,091 | 4,063 |
Total other income | 8,091 | 4,063 |
Loss before income taxes | (1,648,290) | (505,496) |
Provision for income taxes | 1,125 | 800 |
Net loss | $ (1,649,415) | $ (506,296) |
Basic net loss per common share (in Dollars per share) | $ (0.14) | $ (0.05) |
Diluted net loss per common share (in Dollars per share) | $ (0.14) | $ (0.05) |
Weighted average number of common and common equivalent shares: | ||
Basic (in Shares) | 11,748,377 | 9,744,461 |
Diluted (in Shares) | 11,748,377 | 9,744,461 |
Net loss | $ (1,649,415) | $ (506,296) |
Other comprehensive loss, net of tax: | ||
Foreign currency translation | (1,721) | (3,442) |
Comprehensive loss | $ (1,651,136) | $ (509,738) |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Aug. 31, 2020 | May 31, 2020 |
Current Assets: | ||
Cash and cash equivalents | $ 6,964,314 | $ 8,641,027 |
Accounts receivable, less allowance for doubtful accounts of $272,356 and $70,981 as of August 31, 2020 and May 31, 2020, respectively | 1,583,420 | 1,765,871 |
Inventories, net | 4,101,404 | 2,850,836 |
Prepaid expenses and other | 470,934 | 1,509,083 |
Total current assets | 13,120,072 | 14,766,817 |
Property and Equipment, net of accumulated depreciation and amortization of $1,894,375 and $1,867,643 as of August 31, 2020 and May 31, 2020, respectively | 292,235 | 279,379 |
Right of Use Assets, net of accumulated amortization of $288,746 and $231,489 as of August 31, 2020 and May 31, 2020, respectively | 1,654,253 | 1,711,510 |
Investments | 165,324 | 165,324 |
Intangible Assets, net of accumulated amortization of $501,962 and $496,124 as of August 31, 2020 and May 31, 2020, respectively | 215,975 | 168,655 |
Other Assets | 444,631 | 168,193 |
Total Assets | 15,892,490 | 17,259,878 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 1,270,913 | 986,711 |
Accrued compensation | 309,345 | 278,627 |
Lease liability, current portion | 221,201 | 211,809 |
Total current liabilities | 1,801,459 | 1,477,147 |
Lease Liability, net of current portion | 1,510,406 | 1,569,678 |
Total Liabilities | 3,311,865 | 3,046,825 |
Commitments and Contingencies (Notes 5 and 6) | ||
Shareholders' Equity: | ||
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020 | 25,714 | 25,714 |
Common stock, $0.08 par value, 25,000,000 shares authorized, 11,752,589 and 11,740,089 issued and outstanding at August 31, 2020 and May 31, 2020, respectively | 940,205 | 939,205 |
Additional paid-in-capital | 35,231,415 | 35,213,707 |
Accumulated other comprehensive loss | (41,562) | (39,841) |
Accumulated deficit | (23,575,147) | (21,925,732) |
Total Shareholders' Equity | 12,580,625 | 14,213,053 |
Total Liabilities and Shareholders' Equity | 15,892,490 | 17,259,878 |
5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member] | ||
Shareholders' Equity: | ||
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020 | 25,714 | 25,714 |
Preferred Stock [Member] | ||
Shareholders' Equity: | ||
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) | Aug. 31, 2020 | May 31, 2020 |
Allowance for doubtful accounts (in Dollars) | $ 272,356 | $ 70,981 |
Accumulated depreciation and amortization (in Dollars) | 1,894,375 | 1,867,643 |
Accumulated amortization, Right of Use Assets (in Dollars) | 288,746 | 231,489 |
Accumulated amortization, Intangible Assets (in Dollars) | $ 501,962 | $ 496,124 |
Common stock par value (in Dollars per share) | $ 0.08 | $ 0.08 |
Common stock, shares authorized | 25,000,000 | 25,000,000 |
Common stock, shares issued | 11,752,589 | 11,740,089 |
Common stock, shares outstanding | 11,752,589 | 11,740,089 |
5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member] | ||
Preferred Stock, Par Value (in Dollars per share) | $ 0.08 | $ 0.08 |
Preferred Stock, shares authorized | 571,429 | 571,429 |
Preferred Stock, shares issued | 321,429 | 321,429 |
Preferred Stock, shares outstanding | 321,429 | 321,429 |
Preferred Stock [Member] | ||
Preferred Stock, shares issued | 0 | 0 |
Preferred Stock, shares outstanding | 0 | 0 |
Preferred Stock, No Par Value (in Dollars per share) | $ 0 | $ 0 |
Preferred Stock, undesignated shares | 4,428,571 | 4,428,571 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) - 3 months ended Aug. 31, 2020 - USD ($) | Series A Preferred Stock [Member]5% Convertible Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balances at May. 31, 2020 | $ 25,714 | $ 939,205 | $ 35,213,707 | $ (39,841) | $ (21,925,732) | $ 14,213,053 |
Balances (in Shares) at May. 31, 2020 | 321,429 | 11,740,089 | ||||
Exercise of stock options | $ 1,000 | 13,900 | 14,900 | |||
Exercise of stock options (in Shares) | 12,500 | |||||
Foreign currency translation | (1,721) | (1,721) | ||||
Compensation expense in connection with options granted | 3,808 | 3,808 | ||||
Net loss | (1,649,415) | (1,649,415) | ||||
Balances at Aug. 31, 2020 | $ 25,714 | $ 940,205 | $ 35,231,415 | $ (41,562) | $ (23,575,147) | $ 12,580,625 |
Balances (in Shares) at Aug. 31, 2020 | 321,429 | 11,752,589 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 3 Months Ended | |
Aug. 31, 2020 | Aug. 31, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (1,649,415) | $ (506,296) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 32,570 | 35,278 |
Change in provision for allowance on accounts receivable | 201,375 | (6,967) |
Inventory reserve | 5,005 | 2,320 |
Stock option expense | 3,808 | 5,850 |
Reduction in deferred rent liability | (37,971) | |
Amortization of right-of-use asset | 57,257 | 102,456 |
Changes in assets and liabilities: | ||
Accounts receivable | (18,924) | 603,107 |
Inventories | (1,255,573) | (57,568) |
Prepaid expenses and other assets | 1,038,149 | (41,165) |
Reduction in lease liability | (49,880) | (54,796) |
Other assets | (276,438) | |
Accounts payable and accrued expenses | 284,202 | (55,718) |
Accrued compensation | 30,718 | 3,316 |
Net cash used in operating activities | (1,597,146) | (8,154) |
Cash flows from investing activities: | ||
Increase in intangibles | (53,158) | (12,100) |
Purchases of property and equipment | (39,588) | (2,171) |
Net cash used in investing activities | (92,746) | (14,271) |
Cash flows from financing activities: | ||
Proceeds from sale of common stock, net | 112,608 | |
Proceeds from exercise of stock options | 14,900 | 34,028 |
Net cash provided by financing activities | 14,900 | 146,636 |
Effect of exchange rate changes in cash | (1,721) | (3,442) |
Net (decrease) increase in cash and cash equivalents | (1,676,713) | 120,769 |
Cash and cash equivalents at beginning of period | 8,641,027 | 686,785 |
Cash and cash equivalents at end of period | 6,964,314 | 807,554 |
Cash paid during the period for: | ||
Interest | ||
Income taxes | 1,125 | |
Non-cash investing and financing activities: | ||
Establishment of Right-Of-Use Asset per ASC 842 | 1,942,999 | |
Establishment of Lease Liability per ASC 842 | $ 1,980,970 |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 3 Months Ended |
Aug. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting [Text Block] | NOTE 1: BASIS OF PRESENTATION Biomerica, Inc. and Subsidiaries (collectively "the Company") are primarily engaged in the development, manufacture and marketing of medical diagnostic products. The Company develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and other medical conditions. The Company’s medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. The information set forth in these condensed consolidated financial statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries, for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. All adjustments that were made are of a normal recurring nature. The unaudited, Condensed Consolidated Financial Statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2020 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on August 31, 2020 for the fiscal year ended May 31, 2020. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Aug. 31, 2020 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | NOTE 2: SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates. CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash. The Company does not believe it is exposed to significant credit risks. For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively. At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable. Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America. For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured. Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at: August 31,2020 May 31,2020 Raw materials $ 2,219,000 $ 1,635,000 Work in progress 890,000 988,000 Finished products 992,000 228,000 Total $ 4,101,000 $ 2,851,000 Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively. PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively. INTANGIBLES ASSETS, NET Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively. The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019. INVESTMENTS From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020: Exercise Price Weighted Average Option Shares Outstanding May 31, 2020 1,789,251 $ 2.75 Granted 171,000 7.46 Exercised (12,500) 1.20 Cancelled or expired (22,001) 3.43 Outstanding August 31, 2020 1,925,750 $ 3.17 During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20. Total net proceeds to the Company were $14,900. During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46. REVENUE RECOGNITION The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them. The Company also manufactures certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: Three Months Ended August 31,2020 August 31,2019 Clinical lab $ 581,708 $ 890,152 OTC 184,908 199,209 Physician's office 197,331 45,222 Contract Manufacturing 179,859 59,832 Total $ 1,143,806 $ 1,194,415 See Note 4 for additional information regarding revenue concentrations. SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively. INCOME TAXES The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively. FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019. RIGHT-OF-USE ASSETS AND LEASE LIABILITY The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term. NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock. RECENT ACCOUNTING PRONOUNCEMENTS Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements. |
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY | 3 Months Ended |
Aug. 31, 2020 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 3: SHAREHOLDERS’ EQUITY On July 20, 2020, the Company’s outstanding SEC Form S-3 “Shelf” registration statement dated July 20, 2017 expired. This prior registration statement registered an indeterminant number of shares equating to a maximum aggregate offering amount of $45,000,000 of shares. On July 21, 2020, the Company filed with the SEC a new Form S-3 “Shelf” registration statement to replace the registration statement that expired on July 20, 2020. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000. Included in this registration statement was the registration of all of the common shares issued, or to be issued, to Palm Global Small Cap Master Fund LP upon conversion of their Series A 5% Convertible Preferred Stock into common shares. This S-3 registration statement became effective September 30, 2020. |
GEOGRAPHIC INFORMATION
GEOGRAPHIC INFORMATION | 3 Months Ended |
Aug. 31, 2020 | |
Geographic Information Disclosure [Abstract] | |
Geographic Information Disclosure [Text Block] | NOTE 4: GEOGRAPHIC INFORMATION Financial information about foreign and domestic operations and export sales is approximately as follows: Three Months Ended August 31, 2020 August 31, 2019 Revenues from sales to unaffiliated customers: United States $ 134,000 $ 115,000 Asia 347,000 663,000 Europe 591,000 301,000 South America 43,000 47,000 Middle East 29,000 68,000 $ 1,144,000 $ 1,194,000 As of August 31, 2020 and May 31, 2020, approximately $587,000 and $613,000 of Biomerica’s gross inventory and approximately $30,000 and $31,000, of Biomerica’s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively. |
LEASES
LEASES | 3 Months Ended |
Aug. 31, 2020 | |
Disclosure Text Block [Abstract] | |
Lessee, Operating Leases [Text Block] | NOTE 5: LEASES On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. In November 2015, the Company signed the First Amendment to extend the lease until August 31, 2021. As of September 1, 2020, the rent was $23,637 per month. In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The rent is currently $3,239 per month. The Company has one 10-year option to renew at the end of the initial lease period. Biomerica, Inc. is not a guarantor of such lease. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office on a month-to-month basis in Lindau, Germany, as headquarters for BioEurope GmbH, its Germany subsidiary. Components of lease expense include fixed lease expense of $85,946 for the three months ended August 31, 2020. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases which are included in the measurement of the right-of-use asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred. Supplemental cash flow information related to leases for the three months ended August 31, 2020: Operating cash flows from operating leases $ 78,561 Right-of-use assets obtained in exchange for new operating lease liabilities -- Weighted average remaining lease term (in years) 6.02 Weighted average discount rate 6.5 % The maturity of lease liabilities as of August 31, 2020 are as follows: Fiscal Years ending May 31st: 2021 $ 161,927 2022 236,391 2023 262,810 2024 291,328 2025 322,098 Thereafter 457,053 Total $ 1,731,607 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Aug. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 6: COMMITMENTS AND CONTINGENCIES Contracts and Licensing Agreements On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the US FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final US FDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of US FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid. Additionally, the Telcon Agreement provides for a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon. In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In September 2017, the Telcon Agreement was amended to extend the date by which Telcon must attain Korean FDA approval until April 30, 2020. During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As disclosed in the Form 10K filed with the SEC on August 31, 2020, on July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. The Company is continuing to cooperate fully with the SEC’s investigation and provide information as requested. At this time, the Company is unable to predict the duration, scope or outcome of this investigation. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Aug. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | On September 15, 2020, the Company entered into an agreement with Public Health England research institution for the purpose of evaluating the Company’s COVID-19 Rapid Test. On October 5, 2020, the Company entered into a sales agreement with a Ukrainian distributor. The agreement covers a four-year period and the total contract is valued at $480,000. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 3 Months Ended |
Aug. 31, 2020 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | PRINCIPLES OF CONSOLIDATION The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash. The Company does not believe it is exposed to significant credit risks. For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively. At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable. Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America. For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable. |
Cash and Cash Equivalents, Policy [Policy Text Block] | CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. |
Accounts Receivable [Policy Text Block] | ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured. Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. |
Inventory, Policy [Policy Text Block] | INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at: August 31,2020 May 31,2020 Raw materials $ 2,219,000 $ 1,635,000 Work in progress 890,000 988,000 Finished products 992,000 228,000 Total $ 4,101,000 $ 2,851,000 Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively. |
Property, Plant and Equipment, Policy [Policy Text Block] | PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively. |
Goodwill and Intangible Assets, Policy [Policy Text Block] | INTANGIBLES ASSETS, NET Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively. The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019. |
Investment, Policy [Policy Text Block] | INVESTMENTS From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. |
Share-based Payment Arrangement [Policy Text Block] | SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020: Exercise Price Weighted Average Option Shares Outstanding May 31, 2020 1,789,251 $ 2.75 Granted 171,000 7.46 Exercised (12,500) 1.20 Cancelled or expired (22,001) 3.43 Outstanding August 31, 2020 1,925,750 $ 3.17 During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20. Total net proceeds to the Company were $14,900. During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46. |
Revenue [Policy Text Block] | REVENUE RECOGNITION The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them. The Company also manufactures certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: Three Months Ended August 31,2020 August 31,2019 Clinical lab $ 581,708 $ 890,152 OTC 184,908 199,209 Physician's office 197,331 45,222 Contract Manufacturing 179,859 59,832 Total $ 1,143,806 $ 1,194,415 See Note 4 for additional information regarding revenue concentrations. |
Cost of Goods and Service [Policy Text Block] | SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales. |
Research and Development Expense, Policy [Policy Text Block] | RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively. |
Income Tax, Policy [Policy Text Block] | INCOME TAXES The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019. |
Lessee, Leases [Policy Text Block] | RIGHT-OF-USE ASSETS AND LEASE LIABILITY The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term. |
Earnings Per Share, Policy [Policy Text Block] | NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock. |
New Accounting Pronouncements, Policy [Policy Text Block] | RECENT ACCOUNTING PRONOUNCEMENTS Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended |
Aug. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | August 31,2020 May 31,2020 Raw materials $ 2,219,000 $ 1,635,000 Work in progress 890,000 988,000 Finished products 992,000 228,000 Total $ 4,101,000 $ 2,851,000 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Exercise Price Weighted Average Option Shares Outstanding May 31, 2020 1,789,251 $ 2.75 Granted 171,000 7.46 Exercised (12,500) 1.20 Cancelled or expired (22,001) 3.43 Outstanding August 31, 2020 1,925,750 $ 3.17 |
Disaggregation of Revenue [Table Text Block] | Three Months Ended August 31,2020 August 31,2019 Clinical lab $ 581,708 $ 890,152 OTC 184,908 199,209 Physician's office 197,331 45,222 Contract Manufacturing 179,859 59,832 Total $ 1,143,806 $ 1,194,415 |
GEOGRAPHIC INFORMATION (Tables)
GEOGRAPHIC INFORMATION (Tables) | 3 Months Ended |
Aug. 31, 2020 | |
Geographic Information Disclosure [Abstract] | |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended August 31, 2020 August 31, 2019 Revenues from sales to unaffiliated customers: United States $ 134,000 $ 115,000 Asia 347,000 663,000 Europe 591,000 301,000 South America 43,000 47,000 Middle East 29,000 68,000 $ 1,144,000 $ 1,194,000 |
LEASES (Tables)
LEASES (Tables) | 3 Months Ended |
Aug. 31, 2020 | |
Disclosure Text Block [Abstract] | |
Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block] | Supplemental cash flow information related to leases for the three months ended August 31, 2020: Operating cash flows from operating leases $ 78,561 Right-of-use assets obtained in exchange for new operating lease liabilities -- Weighted average remaining lease term (in years) 6.02 Weighted average discount rate 6.5 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Fiscal Years ending May 31st: 2021 $ 161,927 2022 236,391 2023 262,810 2024 291,328 2025 322,098 Thereafter 457,053 Total $ 1,731,607 |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | May 31, 2020 | Aug. 31, 2020 | Aug. 31, 2019 |
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Cash, Uninsured Amount | $ 6,758,700 | ||
Threshold Period Past Due for Write-off of Trade Accounts Receivable | 90 days | ||
Inventory Valuation Reserves | $ 67,000 | $ 72,000 | |
Depreciation, Depletion and Amortization | 26,732 | $ 29,498 | |
Amortization of Intangible Assets | $ 5,838 | 5,780 | |
Equity Method Investment, Ownership Percentage | 6.00% | ||
Proceeds from Stock Options Exercised | $ 14,900 | 34,028 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 171,000 | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ 7.46 | ||
Research and Development Expense | $ 674,693 | 370,466 | |
Deferred Tax Assets, Valuation Allowance | $ 3,175,000 | $ 3,522,000 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 1,925,750 | 1,416,584 | |
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | 321,429 | ||
Minimum [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Property, Plant and Equipment, Useful Life | 5 years | ||
Maximum [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Property, Plant and Equipment, Useful Life | 10 years | ||
Distribution Rights [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Finite-Lived Intangible Asset, Useful Life | 18 years | ||
Purchased Technology Rights [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Finite-Lived Intangible Asset, Useful Life | 10 years | ||
Patents [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Finite-Lived Intangible Asset, Useful Life | 20 years | ||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Concentration Risk, Percentage | 40.10% | 45.80% | |
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Concentration Risk, Percentage | 80.00% | 62.10% | |
Customer Concentration Risk [Member] | South America [Member] | Accounts Receivable [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Concentration Risk, Percentage | 43.60% | ||
Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Concentration Risk, Percentage | 63.80% | 47.50% | |
Supplier Concentration Risk [Member] | Accounts Payable [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Concentration Risk, Percentage | 26.90% | 50.00% | |
Share-based Payment Arrangement, Option [Member] | |||
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 12,500 | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price (in Dollars per share) | $ 1.20 | ||
Proceeds from Stock Options Exercised | $ 14,900 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 171,000 | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ 7.46 |
SIGNIFICANT ACCOUNTING POLICI_4
SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($) | Aug. 31, 2020 | May 31, 2020 |
Inventories [Abstract] | ||
Raw materials | $ 2,219,000 | $ 1,635,000 |
Work in progress | 890,000 | 988,000 |
Finished products | 992,000 | 228,000 |
Total | $ 4,101,404 | $ 2,850,836 |
SIGNIFICANT ACCOUNTING POLICI_5
SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity - Share-based Payment Arrangement, Option [Member] | 3 Months Ended |
Aug. 31, 2020$ / sharesshares | |
SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Line Items] | |
Options Outstanding, Shares | shares | 1,789,251 |
Option Outstanding, Exercise Price Weighted Average | $ / shares | $ 2.75 |
Option Granted, Shares | shares | 171,000 |
Option Granted, Exercise Price Weighted Average | $ / shares | $ 7.46 |
Option Exercised, Shares | shares | (12,500) |
Option Exercised, Exercise Price Weighted Average | $ / shares | $ 1.20 |
Option Cancelled or expired, Shares | shares | (22,001) |
Option Cancelled or expired, Exercise Price Weighted Average | $ / shares | $ 3.43 |
Options Outstanding, Shares | shares | 1,925,750 |
Option Outstanding, Exercise Price Weighted Average | $ / shares | $ 3.17 |
SIGNIFICANT ACCOUNTING POLICI_6
SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($) | 3 Months Ended | |
Aug. 31, 2020 | Aug. 31, 2019 | |
Disaggregation of Revenue [Line Items] | ||
Revenue From Customers | $ 1,143,806 | $ 1,194,415 |
Clinical Lab [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenue From Customers | 581,708 | 890,152 |
OTC [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenue From Customers | 184,908 | 199,209 |
Physicians Office [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenue From Customers | 197,331 | 45,222 |
Contract Manufacturing [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenue From Customers | $ 179,859 | $ 59,832 |
SHAREHOLDERS' EQUITY (Details)
SHAREHOLDERS' EQUITY (Details) - USD ($) | Jul. 21, 2020 | Jul. 20, 2020 |
Common Stock [Member] | Maximum [Member] | ||
SHAREHOLDERS' EQUITY (Details) [Line Items] | ||
Proceeds from Issuance of Common Stock | $ 90,000,000 | $ 45,000,000 |
GEOGRAPHIC INFORMATION (Details
GEOGRAPHIC INFORMATION (Details) - MEXICO - USD ($) | Aug. 31, 2020 | May 31, 2020 |
GEOGRAPHIC INFORMATION (Details) [Line Items] | ||
Inventory, Gross | $ 587,000 | $ 613,000 |
Property, Plant and Equipment, Net | $ 30,000 | $ 31,000 |
GEOGRAPHIC INFORMATION (Detai_2
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($) | 3 Months Ended | |
Aug. 31, 2020 | Aug. 31, 2019 | |
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | $ 1,143,806 | $ 1,194,415 |
UNITED STATES | ||
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | 134,000 | 115,000 |
Asia [Member] | ||
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | 347,000 | 663,000 |
Europe [Member] | ||
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | 591,000 | 301,000 |
South America [Member] | ||
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | 43,000 | 47,000 |
Middle East [Member] | ||
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items] | ||
Net sales | $ 29,000 | $ 68,000 |
LEASES (Details)
LEASES (Details) - USD ($) | Jun. 18, 2009 | Nov. 30, 2016 | Aug. 31, 2020 |
LEASES (Details) [Line Items] | |||
Operating Leases, Rent Expense | $ 85,946 | ||
Building In Irvine California [Member] | |||
LEASES (Details) [Line Items] | |||
Operating Leases, Rent Expense | $ 23,637 | ||
Operating Lease Initiation Date | Sep. 1, 2009 | ||
Lease Expiration Date | Aug. 31, 2016 | ||
Building In Irvine California [Member] | First Amendment To Lease [Member] | |||
LEASES (Details) [Line Items] | |||
Lease Expiration Date | Aug. 31, 2021 | ||
MEXICO | Property Available for Operating Lease [Member] | |||
LEASES (Details) [Line Items] | |||
Operating Leases, Rent Expense | $ 3,239 | ||
Lease Expiration Period | 10 years |
LEASES (Details) - Supplemental
LEASES (Details) - Supplemental cash flow information related to leases | 3 Months Ended |
Aug. 31, 2020USD ($) | |
Supplemental cash flow information related to leases [Abstract] | |
Operating cash flows from operating leases | $ 78,561 |
Right-of-use assets obtained in exchange for new operating lease liabilities | |
Weighted average remaining lease term (in years) | 6 years 7 days |
Weighted average discount rate | 6.50% |
LEASES (Details) - The maturity
LEASES (Details) - The maturity of lease liabilities | Aug. 31, 2020USD ($) |
The maturity of lease liabilities [Abstract] | |
2021 | $ 161,927 |
2022 | 236,391 |
2023 | 262,810 |
2024 | 291,328 |
2025 | 322,098 |
Thereafter | 457,053 |
Total | $ 1,731,607 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) - USD ($) | May 25, 2016 | Jun. 25, 2020 |
University Of Texas Health Science Center [Member] | ||
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Clinical Trial Agreement Maximum Budgeted Costs | $ 139,850 | |
Telcon Agreement [Member] | ||
COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||
Accrued Fees and Other Revenue Receivable | $ 1,250,000 | |
Stock Issued During Period, Shares, Other (in Shares) | 83,333 | |
Proceeds from Fees Received | $ 250,000 | |
Royalty Percentage | 15.00% |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) | Oct. 05, 2020USD ($) |
Ukrainian Distributor [Member] | Subsequent Event [Member] | |
SUBSEQUENT EVENTS (Details) [Line Items] | |
Contract with Customer, Asset, Sale | $ 480,000 |